<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Reversibility in vivo of <z:hpo ids='HP_0011009'>acute</z:hpo> platelet <z:mp ids='MP_0005048'>thrombosis</z:mp> in response to specific <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> is analyzed with <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> that develop in segments (1 cm) of porcine carotid arteries externally crushed with a hemostat </plain></SENT>
<SENT sid="1" pm="."><plain>Most <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> fill the lumens of the injured segments (ca </plain></SENT>
<SENT sid="2" pm="."><plain>1 cm x 3 mm, 1 x w) within 30 min and comprise masses of platelets interpenetrated with neutrophil-lined seepage channels of blood </plain></SENT>
<SENT sid="3" pm="."><plain>Continuous quantitative assay of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> mass is provided by a gamma detector placed over the injured segments to collect counts from 111In-labeled platelets </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> established 30 min after injury, otherwise stable for 6 h, clear during 30-60 min of continuous infusion of either hirudin, tick <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> or activated porcine protein C, or intermittent activation of endogenous protein C with a latent thrombin reagent </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="3" ids="50249">Anticoagulant</z:chebi> dose-dependence of <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> clearance is established for hirudin between 0.01 and 1.0 mg/kg/min </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">Thrombi</z:e> become progressively refractory to hirudin between 0.5 and 6 h after injury </plain></SENT>
<SENT sid="7" pm="."><plain>Neither <z:chebi fb="5" ids="28304">heparin</z:chebi> no low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> in full (clinical) <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> doses yield significant dethrombosis </plain></SENT>
<SENT sid="8" pm="."><plain>It is concluded that, within time limits, controlled thrombin generation in platelet <z:e sem="disease" ids="C0087086" disease_type="Disease or Syndrome" abbrv="">thrombi</z:e> maintains platelet cohesion without catalyzing irreversible platelet aggregation or clotting of fibrinogen </plain></SENT>
</text></document>